Bill seeks to introduce ‘pull’ incentive for antibiotics

Two members of the House Energy and Commerce Committee introduced legislation that would create a new “pull” incentive pathway for priority antibiotics, providing manufacturers a transferable award that could be worth $1 billion or more. The bill, the Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018, aims to de-link the returns an antibiotics company receives from the volume of drugs sold by providing a high value award upon approval of antibiotics to treat multi-drug resistant pathogens. The bill, H.R. 6294, is sponsored by Rep. John Shimkus (R-Ill.) and co-sponsored by Rep. Tony Cárdenas (D-Calif.).

The legislation comes a few weeks after FDA Commissioner Scott Gottlieb proposed a license-based reimbursement model for antibiotics that would de-link the volume of sales from the revenues a company would receive (see "Emergency Preparedness")...